335 related articles for article (PubMed ID: 38459229)
1. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Polyzos SA; Targher G
Curr Obes Rep; 2024 Jun; 13(2):242-255. PubMed ID: 38459229
[TBL] [Abstract][Full Text] [Related]
2. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
Larner DP; Morgan SA; Gathercole LL; Doig CL; Guest P; Weston C; Hazeldine J; Tomlinson JW; Stewart PM; Lavery GG
Endocrinology; 2016 Sep; 157(9):3493-504. PubMed ID: 27384305
[TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
4. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
5. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.
Ahmed A; Rabbitt E; Brady T; Brown C; Guest P; Bujalska IJ; Doig C; Newsome PN; Hubscher S; Elias E; Adams DH; Tomlinson JW; Stewart PM
PLoS One; 2012; 7(2):e29531. PubMed ID: 22363403
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
Tomlinson JW; Sherlock M; Hughes B; Hughes SV; Kilvington F; Bartlett W; Courtney R; Rejto P; Carley W; Stewart PM
J Clin Endocrinol Metab; 2007 Mar; 92(3):857-64. PubMed ID: 17200165
[TBL] [Abstract][Full Text] [Related]
8. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
Aggeletopoulou I; Tsounis EP; Triantos C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
[TBL] [Abstract][Full Text] [Related]
12. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
13. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
14. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
15. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
16. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
[TBL] [Abstract][Full Text] [Related]
17. Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN/Ob obese rats.
Sakamuri VP; Ananthathmakula P; Veettil GN; Ayyalasomayajula V
Nutr J; 2011 Jun; 10():70. PubMed ID: 21696642
[TBL] [Abstract][Full Text] [Related]
18. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
[TBL] [Abstract][Full Text] [Related]
19. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]